4124-30-5 Usage
Description
Dichloroacetic anhydride is a clear colorless liquid that serves as an acylating agent. It has been evaluated for its potential to induce autoimmune responses and is known for its use in various chemical reactions and processes.
Uses
1. Used in Pharmaceutical Industry:
Dichloroacetic anhydride is used as an acylating agent for the acylation of 10-Deacetylbaccatin III using Pseudomonas cepacia. This application is crucial in the synthesis of certain pharmaceutical compounds.
2. Used in Chemical Industry:
Dichloroacetic anhydride is used in the preparation of cellulose dichloroacetates, which are important in various chemical processes and applications.
3. Used in Research and Development:
As an acylating agent, dichloroacetic anhydride is also utilized in research and development for studying its effects on inducing autoimmune responses and exploring its potential in creating new compounds and materials.
Check Digit Verification of cas no
The CAS Registry Mumber 4124-30-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,1,2 and 4 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 4124-30:
(6*4)+(5*1)+(4*2)+(3*4)+(2*3)+(1*0)=55
55 % 10 = 5
So 4124-30-5 is a valid CAS Registry Number.
InChI:InChI=1/C4H2Cl4O3/c5-1(6)3(9)11-4(10)2(7)8/h1-2H
4124-30-5Relevant articles and documents
Ctc-[Pt(NH3)2(cinnamate)(valproate)Cl2] is a highly potent and low-toxic triple action anticancer prodrug
Li, Yang,Shi, Shan,Zhang, Shurong,Gan, Zongjie,Wang, Xin,Zhao, Xudong,Zhu, Yijian,Cao, Meiting,Wang, Xiaoyue,Li, Wei
supporting information, p. 11180 - 11188 (2021/08/25)
Pt(iv) prodrugs have gained tremendous attention due to their indisputable advantages compared to cisplatin. Herein, new Pt(iv) derivatives with cinnamic acid at the first axial position, and inhibitor of matrix metalloproteinases-2 and-9, histone deacetylase, cyclooxygenase or pyruvate dehydrogenase at the second axial position are constructed to develop multi-action prodrugs. We demonstrate that Pt(iv) prodrugs are reducible and have superior antiproliferative activity with IC50 values at submicromolar concentrations. Notably, Pt(iv) prodrugs exhibit highly potent anti-tumour activity in an in vivo breast cancer model. Our results support the view that a triple-action Pt(iv) prodrug acts via a synergistic mechanism, which involves the effects of CDDP and the effects of axial moieties, thus jointly leading to the death of tumour cells. These findings provide a practical strategy for the rational design of more effective Pt(iv) prodrugs to efficiently kill tumour cells by enhancing their cellular accumulation and tuning their canonical mechanism.